Published in Clin Cancer Res on April 01, 2007
Safety Study of CALAA-01 to Treat Solid Tumor Cancers | NCT00689065
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Label-free technologies for quantitative multiparameter biological analysis. Anal Bioanal Chem (2009) 1.66
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol (2009) 1.53
Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem (2009) 1.31
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A (2009) 1.26
Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer (2009) 1.14
siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12
Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci (Lond) (2013) 1.08
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov (2015) 1.02
Retinoblastoma protein plays multiple essential roles in the terminal differentiation of Sertoli cells. Mol Endocrinol (2009) 1.00
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release (2012) 0.99
A genome-wide siRNA screen reveals positive and negative regulators of the NOD2 and NF-κB signaling pathways. Sci Signal (2013) 0.99
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A (2014) 0.99
Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes. Free Radic Biol Med (2011) 0.98
Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics (2014) 0.96
A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer (2011) 0.95
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res (2013) 0.95
Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing (2009) 0.92
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol (2008) 0.89
Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res (2012) 0.89
Merging molecular imaging and RNA interference: early experience in live animals. J Cell Biochem (2008) 0.87
Oocyte-expressed yes-associated protein is a key activator of the early zygotic genome in mouse. Cell Res (2016) 0.86
Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. J Drug Deliv (2012) 0.84
Reciprocal regulation of autophagy and dNTP pools in human cancer cells. Autophagy (2014) 0.84
Personalized cancer approach: using RNA interference technology. World J Surg (2011) 0.83
MicroRNAs and cancer therapeutics. Pharm Res (2011) 0.81
Phenotypes of Th lineages generated by the commonly used activation with anti-CD3/CD28 antibodies differ from those generated by the physiological activation with the specific antigen. Cell Mol Immunol (2014) 0.80
Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. BMC Cancer (2014) 0.79
The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. PLoS One (2014) 0.78
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease. ISRN Oncol (2012) 0.77
A novel assay revealed that ribonucleotide reductase is functionally important for interstrand DNA crosslink repair. Bioorg Med Chem (2015) 0.76
A Small Indel Mutant Mouse Model of Epidermolytic Palmoplantar Keratoderma and Its Application to Mutant-specific shRNA Therapy. Mol Ther Nucleic Acids (2016) 0.75
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget (2016) 0.75
Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems. Kona (2016) 0.75
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A (2007) 5.17
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91
MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res (2007) 3.37
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res (2006) 3.22
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A (2009) 2.72
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol (2003) 2.48
PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol (2004) 2.32
Nanotechnology and cancer. Annu Rev Med (2008) 2.25
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 2.08
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
Development of universal antidotes to control aptamer activity. Nat Med (2009) 1.93
Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J Biol Chem (2007) 1.85
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics (2011) 1.81
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Localized expression of small RNA inhibitors in human cells. Mol Ther (2003) 1.78
Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res (2003) 1.77
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res (2009) 1.73
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem (2007) 1.71
Lack of interferon response in animals to naked siRNAs. Nat Biotechnol (2004) 1.71
Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther (2005) 1.67
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (2004) 1.66
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 1.64
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A (2009) 1.63
Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng (2008) 1.60
siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res (2005) 1.60
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res (2006) 1.59
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett (2005) 1.58
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A (2012) 1.52
A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett (2009) 1.49
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol (2009) 1.47
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol (2005) 1.45
Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem (2003) 1.44
Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol (2006) 1.44
Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res (2009) 1.43
A combustion-free methodology for synthesizing zeolites and zeolite-like materials. Nature (2003) 1.43
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Functional siRNA expression from transfected PCR products. RNA (2002) 1.42
Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A (2011) 1.41
Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol (2005) 1.41
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther (2004) 1.40
Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem (2004) 1.40
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39
Tin-containing zeolites are highly active catalysts for the isomerization of glucose in water. Proc Natl Acad Sci U S A (2010) 1.38
CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci U S A (2009) 1.38
A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization. Bioconjug Chem (2005) 1.37
HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res (2005) 1.37
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng (2007) 1.36
Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res (2011) 1.36
Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3'UTR. Nucleic Acids Res (2009) 1.35
Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem (2003) 1.35
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol (2004) 1.34
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood (2008) 1.34
A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res (2005) 1.34
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol Ther (2007) 1.34
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep (2006) 1.32
Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J (2007) 1.31
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res (2011) 1.30
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther (2003) 1.29
RNAi and the P-body connection. Nat Cell Biol (2005) 1.29